2020 transcripts of 4 major listed CAR-T pharmaceutical companies announced

This month, the four major domestic listed CAR-T pharmaceutical companies-Legend Bio, Genxi Bio, Yongtai Bio, and WuXi Junuo successively released 2020 performance reports.

Legendary creatures

As the first share of CAR-T in China, the report shows that Legendary Bio will have a revenue of 75.

Although the net loss expanded to 335 million U.

At present, the core product cilta-cel has officially submitted a marketing application to the FDA in December 2020 , and has obtained the U.

Yongtai Biological

In the past two financial years of 2018 and 2019, Yongtai Biotechnology did not have main income.

Yongtai Biotech claims to be the first cell company in China to obtain an IND approval after the Wei Zexi incident.

EAL is the only solid tumor cell immunotherapy product approved to enter Phase II/III clinical trials , and its indication is liver cancer, which has a huge market in China, and is also developingApplications in the fields of gastric cancer , lung cancer, colorectal cancer and glioma.

In terms of industrialization, Yongtai Biotech stated in its financial report that for the 6-hour transportation radius of EAL, in addition to the substantial construction of the headquarters base in Beijing, it is planning to establish in the Yangtze River Delta region, the Pearl River Delta region and other major cities.

WuXi Juno

Whether or not China's first CAR-T product can be born, WuXi Giant Nuo has attracted much attention.

According to WuXi Junuo’s financial report, there is no revenue because it has not yet been commercialized, and operating losses mainly come from R&D expenditures.

At present, WuXi Giant Nuo has 7 candidate cellular immunotherapy products, which are mainly focused on solid tumor treatment.

The most important point of WuXi Juno’s advantage is its “famous background.

Genxi Bio

Genxi Bio's current revenue has not yet been disclosed.

At present, Genxi Bio's core product, the dual antigen autologous CAR-T cell therapy GC012F targeting BCMA/CD19, is undergoing a phase I clinical trial in China for the treatment of multiple myeloma patients who have relapsed or are refractory after previous treatment.

In addition, its CD19-targeting autologous CAR-T cell therapy GC019F, allogeneic candidate product GC027, and GC007g derived from healthy donor T cells have all entered the clinic.